Myocardial‐Targeting Tannic Cerium Nanocatalyst Attenuates Ischemia/Reperfusion Injury
Angewandte Chemie International Edition · 25.09.2023 · 62 (39)
DOI: 10.1002/anie.202305576 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 11.07.2023. Verfasst von Liping Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Ceramics, Chinese Academy of Sciences, Research Unit of Nanocatalytic Medicine in Specific Therapy for Serious Disease, Chinese…. Hauptthemen laut MEDLINE: Myocardial Reperfusion Injury, Myocardial Infarction. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Key Research Program of Frontier Science, Chinese Academy of Sciences.
Abstract (Originalsprache)
Ischemic heart disease (IHD) is one of the leading causes of death worldwide. Medications or surgery have been considered as effective protocols to treat IHD for decades. Yet the reperfusion of the blood flow frequently leads to the generation of excessive reactive oxygen species (ROS), causing prominent and irreversible damage to the cardiomyocytes. In the present work, tannic acid‐assembled tetravalent cerium (TA−Ce) nanocatalysts with appealing cardiomyocyte‐targeting and antioxidation capability have been synthesized and applied for the effective and biocompatible ischemia/reperfusion injury therapeutics. TA−Ce nanocatalysts could effectively rescue the cardiomyocytes from oxidative stress induced by H 2 O 2 challenge as well as oxygen‐glucose deprivation in vitro. In the murine ischemia/reperfusion model, cardiac accumulation and intracellular ROS scavenging could be achieved against the pathology, substantially reducing the myocardial infarct area and recovering heart functionality. This work illuminates the design of nanocatalytic metal complexes and their therapeutic prospects in ischemic heart diseases with high effectiveness and biocompatibility, paving the way for the clinical translation from bench to bedside.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Ceramics, Chinese Academy of Sciences, Research Unit of Nanocatalytic Medicine in Specific Therapy for Serious Disease, Chinese Academy of Medical Sciences (2021RU012), Shanghai, 200050, P. R. Chin…
- Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
- Shanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, School of Medicine, Tongji University, Shanghai, 200072, P. R. China.
- Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, 610041, China.
ORCID-Profile: Minfeng Huo, Jianlin Shi
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Key Research Program of Frontier Science, Chinese Academy of Sciences
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine
- National Key Research and Development Program of China
- Shanghai Rising-Star Program
Zitieren
APA
Wang, L., Qiu, S., Li, X., Zhang, Y., Huo, M., & Shi, J. (2023). Myocardial‐Targeting Tannic Cerium Nanocatalyst Attenuates Ischemia/Reperfusion Injury. Angewandte Chemie International Edition, 62(39). https://doi.org/10.1002/anie.202305576
Vancouver
Wang L, Qiu S, Li X, Zhang Y, Huo M, Shi J. Myocardial‐Targeting Tannic Cerium Nanocatalyst Attenuates Ischemia/Reperfusion Injury. Angewandte Chemie International Edition. 2023;62(39). doi:10.1002/anie.202305576
BibTeX
@article{Wang2023,
author = {Wang, Liping and Qiu, Shuwen and Li, Xi and Zhang, Yabing and Huo, Minfeng and Shi, Jianlin},
title = {Myocardial‐Targeting Tannic Cerium Nanocatalyst Attenuates Ischemia/Reperfusion Injury},
journal = {Angewandte Chemie International Edition},
year = {2023},
volume = {62},
number = {39},
doi = {10.1002/anie.202305576}
}
EUVIMED